Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

29452 ARTÍCULOS , VIENDO DEL 29101 AL 29115

Spectral Biomarkers of Functional Brain Network Alteration in Alzheimer's Disease

Behrouzinia S, Afshar M, Khanteymoori A.

Curr Alzheimer Res. 2025;22(11):837-849. doi: 10.2174/0115672050434251251008104505.

Malondialdehyde in cognitive impairment: A systematic review and meta-analysis

Zoroddu S, Sedda S, Mangoni AA, Carru C, Zinellu A.

Neurosci Biobehav Rev. 2026 Feb;181:106531. doi: 10.1016/j.neubiorev.2025.106531. Epub 2025 Dec 20.

Exosomes in Alzheimer's disease: From pathogenesis to therapeutics-A comprehensive review of diagnostic and drug delivery applications

Shahlaei M, Afkhami H, Ahmadieh-Yazdi A, Mirmazloumi SH, Sahraei SS, Akbari M, Yang P, Manoochehri H, Tanzadehpanah H, Mahaki H, Sundararaman A, Mohan S, Sheykhhasan M, Al-Musawi S, Dama P.

Biomed Pharmacother. 2025 Nov;192:118548. doi: 10.1016/j.biopha.2025.118548. Epub 2025 Sep 22.

Targeting Transferrin Receptor 1 for Enhancing Drug Delivery Through the Blood-Brain Barrier for Alzheimer's Disease

Shen X, Li H, Zhang B, Li Y, Zhu Z.

Int J Mol Sci. 2025 Oct 8;26(19):9793. doi: 10.3390/ijms26199793.

A systematic review and meta-analysis of pteridines in mild cognitive impairment and Alzheimer's disease

Mangoni AA, Zinellu A.

BMC Geriatr. 2025 Feb 13;25(1):94. doi: 10.1186/s12877-025-05760-9.

Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions

Knopman DS.

Alzheimers Dement. 2025 Jan;21(1):e14043. doi: 10.1002/alz.14043. Epub 2024 Dec 24.

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease

Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ.

J Prev Alzheimers Dis. 2025 Nov;12(9):100337. doi: 10.1016/j.tjpad.2025.100337. Epub 2025 Sep 5.

Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations

Deverka PA, Arias JJ, Lin GA, Zwerling J, Phillips KA.

J Alzheimers Dis. 2025 May;105(2):433-442. doi: 10.1177/13872877251329394. Epub 2025 Apr 1.

Alzheimer's Disease Clinical Trials: What Have We Learned From Magnetic Resonance Imaging

By S, Kahl A, Cogswell PM.

J Magn Reson Imaging. 2025 Feb;61(2):579-594. doi: 10.1002/jmri.29462. Epub 2024 Jun 20.

Plasma adiponectin and biomarker-confirmed Alzheimer's disease in a tertiary memory clinic

Sindzingre L, Bouaziz-Amar E, Mouton-Liger F, Cognat E, Dumurgier J, Götze K, Martinet M, Vrillon A, Paquet C, Lilamand M.

J Neuroendocrinol. 2025 Apr;37(4):e13493. doi: 10.1111/jne.13493. Epub 2025 Jan 22.

Unveiling blood biomarkers for neuronal hyperplasticity: Insights from AD molecular subtyping, a comprehensive review

Sharma N, Kim D, Sharma H, Kim MI, Lee H, Kim M, Ryoo N, Kang MJ, Pyun JM, Park YH, Ryu J, Oh HJ, Yang HS, Kim HR, Kim GH, Han S, Yang Y, Youn YC, Teunissen C, Zetterberg H, Scheltens P, An SSA, Kim YB, Kim S; Alzheimer's Disease All Markers (ADAM) Research Group.

Alzheimers Dement. 2025 Jul;21(7):e70475. doi: 10.1002/alz.70475.

Pulse pressure as a predictor of Alzheimer's disease biomarkers and cognitive decline: The moderating role of APOE ε4

Jung JH, Kong N, Lee S; A4 and LEARN Study Teams.

J Prev Alzheimers Dis. 2025 Dec;12(10):100363. doi: 10.1016/j.tjpad.2025.100363. Epub 2025 Sep 3.

The Effect of APOE ε4 on Alzheimer's Disease Fluid Biomarkers: A Cross-Sectional Study Based on the COAST

Zhao B, Zang P, Quan M, Wang Q, Guo D, Jia J, Wang W.

CNS Neurosci Ther. 2025 Jan;31(1):e70202. doi: 10.1111/cns.70202.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias